new-recommended-broker-banner new-recommended-broker-banner
Practice Stock Trading Your capital is at risk

NanoViricides (NNVC) Stock Rallied 49.9% on Positive Results for Its COVID-19 Drug

Updated: 21 Sep 2021

NanoViricides Inc (NYSEAMERICAN: NNVC) stock rallied 49.9% after results of an animal trial showed that its COVID-19 drug candidate showed promise when encapsulated with Gilead’s remdesivir.

The company has two drug candidates; the first is known as NV-CoV-2, which does not encapsulate remdesivir, while the second is known as NV-CoV-2-R, which is similar to NV-CoV-2 but encapsulates remdesivir.

Nanoviricides’ noted that the animal trial showed that double the remdesivir was retained in the blood plasma when administered NV-CoV-2-R compared to when Remdesivir was administered independently on the very first day.


The levels of Remdesivir retained in the blood kept rising with repeated dosing, with the level of remdesivir maintained in blood plasma after the fifth dose being 75% higher in the NV-Cov-2-R group compared to the remdesivir group.

As a bonus, the study revealed that the increased retention of remdesivir did not result in a corresponding increase in blood plasma toxicity.

Investors cheered the results, which indicate that NV-CoV-2-R could be a tremendous pan-coronavirus cure in the future.

Nanoviricides (NNVC) stock price.

Tradingview chart of Nanoviricides stock price 21-09-2021

NNVC stock rallied 49.86% during the premarket session to trade at $5.68, rising from Monday’s closing price of $3.79.

Should You Invest in NanoViricides Shares?

One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .